EASD 2026: GLP-1 and SGLT2 treatment lowers mortality in heart failure patients

At EASD 2026, research was presented that showed initial correlations between the use of SGLT2 inhibitors and GLP-1 agonists in diabetic patients undergoing treatment for acute heart failure. At EASD 2026, retrospective research was presented that showed initial correlations between the use of SGLT2 inhibitors and GLP-1 agonists in diabetic patients undergoing treatment for acute heart failure in the hospital setting. SGLT2 inhibitors such as dapagliflozin are a class of drugs used to manage type 2 diabetes (T2D) and heart failure. Credit: Photo Nature Travel / Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth…

Source: Clinical Trials Arena